Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Customer Concentration by Year
Customer Concentration — McKesson Corp. share of gross product revenues (%) (%)
Vertex Pharmaceuticals Customer Concentration: 2,200.0% in FY2025, down 400.0 pts from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-K Note (Significant Revenue & Receivable Concentrations).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Customer Concentration — McKesson Corp. share of gross product revenues (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,200.0% | -400.0 pts | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 2,600.0% | 0.0 pts | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 2,600.0% | +100.0 pts | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 2,500.0% | +300.0 pts | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 2,200.0% | +200.0 pts | Form 10-K (filed 2024-02-15) ↗ |
| FY2020 | Dec 31, 2020 | 2,000.0% | +300.0 pts | Form 10-K (filed 2023-02-10) ↗ |
| FY2019 | Dec 31, 2019 | 1,700.0% | +300.0 pts | Form 10-K (filed 2022-02-09) ↗ |
| FY2018 | Dec 31, 2018 | 1,400.0% | +400.0 pts | Form 10-K (filed 2021-02-11) ↗ |
| FY2017 | Dec 31, 2017 | 1,000.0% | 0.0 pts | Form 10-K (filed 2020-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 1,000.0% | – | Form 10-K (filed 2019-02-13) ↗ |
Breakdown
What makes up customer Concentration
- McKesson Corp. — Share of gross accounts receivable (%)1,900.0% · FY2025
- Accredo Health Group — Share of gross product revenues (%)1,200.0% · FY2025
- Accredo Health Group — Share of gross accounts receivable (%)1,000.0% · FY2025
- Lloyds Pharmacy Clinical Homecare — Share of gross product revenues (%)1,000.0% · FY2025
- Lloyds Pharmacy Clinical Homecare — Share of gross accounts receivable (%)1,000.0% · FY2025
- Walgreen Co. — Share of gross product revenues (historical, %)1,000.0% · FY2024
- Walgreen Co. — Share of gross accounts receivable (historical, %)1,000.0% · FY2024
- CVS Caremark — Share of gross product revenues (historical, %)1,000.0% · FY2017
- CVS Caremark — Share of gross accounts receivable (historical, %)1,700.0% · FY2016
Cite this data
StockData. (2026). Vertex Pharmaceuticals Customer Concentration (%), annual FY2016–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cust-conc-hdr
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.